TY - JOUR T1 - Alvolar lymphocytes (AL) in patients with non-small cell lung cancer (NSCLC). Data from tumor-affected lobe JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.congress-2015.PA3806 VL - 46 IS - suppl 59 SP - PA3806 AU - Joanna Wozniak AU - Tomasz Wandtke AU - Piotr Kopinski AU - Joanna Chorostowska AU - Agata Gizycka AU - Cezary Rybacki AU - Iwona Patyk AU - Blazej Przybyslawski AU - Andrzej Redziak Y1 - 2015/09/01 UR - http://erj.ersjournals.com/content/46/suppl_59/PA3806.abstract N2 - Introduction: The mechanisms of local immune suppression in NSCLC, including alterations in AL function, proliferation and apoptosis have not been fully explored.Aim: To evaluate AL cell cycle and cytotoxic properties of AL obtained from patients diagnosed with NSCLC.Methods: Bronchoalveolar lavage (BAL) harvested from stage I-IIa NSCLC patients (squamous cell carcinoma, n=6 and adenocarcinoma, n=10) was analyzed for AL phenotype, incl. cytotoxicity markers (FasL, TRAIL, granzyme B), and apoptosis: 1) cell cycle stained with propidium iodide (detection of sub-G1 cycle phase), 2) flow cytometry scatter properties.Results: In NSCLC patients, AL apoptosis rate was lower as compared to controls. Statistical significance was proved in adenocarcinoma smokers (0.3±0.4 vs 1.4±1.2% for sub-G1, p<0.05, median±SEM). AL did not proliferate. The relative AL number was increased in NSCLC (significant for smokers). There was increase in cytotoxic phenotype AL percentage: CD4(CD8)+CD28–CD27–TRAIL+, with only few memory or T-regulatory cells. Granzyme B was found in 21-84% of AL, including CD4 cells.Conclusion: Unexpectedly, our observations suggest that NSCLC-induced suppression of alveolar lymphocytes does not exist, or it occurs at a relatively low level. However, we did not examine tumor infiltrating cells. AL system may be potentially used for immune therapy in early stage NSCLC. ER -